HSV thymidine kinase gene therapy

Drug Profile

HSV thymidine kinase gene therapy

Alternative Names: Retrovector™

Latest Information Update: 22 Jul 2010

Price : $50

At a glance

  • Originator AVAX Technologies; Edison Biotechnology Institute; Novartis; Scientific Institute San Raffaele; Universite Pierre et Marie Curie
  • Developer AVAX Technologies; Aventis Gencell; Edison Biotechnology Institute; Human Gene Therapy Research Institute (Des Moines); Novartis; Scientific Institute San Raffaele
  • Class Gene therapies
  • Mechanism of Action Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Graft-versus-host disease; Hepatocellular carcinoma; Leukaemia; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 20 May 2002 Interneuron Pharmaceuticals is now called Indevus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top